Lifesci Capital Cuts Earnings Estimates for DBV Technologies

Key Points

• Analysts at Lifesci Capital have significantly decreased their Q3 2025 earnings per share (EPS) estimate for DBV Technologies to ($1.25), down from a prior forecast of ($0.70).
• DBV Technologies' current full-year earnings consensus estimate is expected to be ($7.05) per share, reflecting ongoing financial challenges for the company.
• Shares of DBV Technologies have seen a decline of 9.5%, with the stock currently trading at around $8.51, compared to a 12-month high of $12.78.

DBV Technologies S.A. (NASDAQ:DBVT - Free Report) - Equities research analysts at Lifesci Capital lowered their Q3 2025 earnings per share (EPS) estimates for shares of DBV Technologies in a research note issued to investors on Wednesday, July 30th. Lifesci Capital analyst S. Slutsky now expects that the company will earn ($1.25) per share for the quarter, down from their previous forecast of ($0.70). Lifesci Capital currently has a "Strong-Buy" rating on the stock. The consensus estimate for DBV Technologies' current full-year earnings is ($7.05) per share. Lifesci Capital also issued estimates for DBV Technologies' Q4 2025 earnings at ($1.25) EPS, FY2025 earnings at ($5.40) EPS and FY2026 earnings at ($1.65) EPS.

Other analysts have also recently issued reports about the company. The Goldman Sachs Group raised DBV Technologies to a "sell" rating and set a $7.25 price objective on the stock in a report on Thursday, May 29th. Wall Street Zen cut DBV Technologies from a "hold" rating to a "sell" rating in a report on Friday, July 18th. HC Wainwright boosted their target price on DBV Technologies from $7.00 to $16.00 and gave the company a "buy" rating in a research report on Monday, May 5th. JMP Securities reissued a "market outperform" rating and set a $21.00 target price on shares of DBV Technologies in a research report on Thursday, June 26th. Finally, Citigroup reissued an "outperform" rating on shares of DBV Technologies in a research report on Tuesday, May 27th. Two analysts have rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $14.75.

DBV Technologies Stock Performance

Shares of DBVT traded up $0.69 during mid-day trading on Friday, hitting $9.50. 28,869 shares of the stock were exchanged, compared to its average volume of 216,966. The company has a market cap of $260.21 million, a PE ratio of -1.99 and a beta of -0.58. DBV Technologies has a 52-week low of $2.20 and a 52-week high of $12.78. The firm has a 50-day moving average of $9.50 and a two-hundred day moving average of $7.48.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The company reported ($1.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($1.34). The firm had revenue of $1.74 million for the quarter, compared to analysts' expectations of $0.64 million. DBV Technologies had a negative return on equity of 287.15% and a negative net margin of 3,220.49%.

Hedge Funds Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new position in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies at the end of the most recent quarter. Hedge funds and other institutional investors own 71.74% of the company's stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.